ACLX News and Press, Arcellx Inc. From 06/16/22

AC Immune (ACIU) -32%  as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx (ACLX) -10% on upsizing of follow-on public offering of 7M shares at $...

Arcellx Announces Upsizing and Pricing of Follow-On Public Offering PR Newswire -- Public Offering of 7,000,000 Shares of Common Stock for Gross Proceeds of $112 Million -- REDWOOD City, Calif. , June 15, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ...

Gainers: Gelesis (GLS) +14%. Entrada Therapeutics (TRDA) +10%. Rhythm Pharmaceuticals (RYTM) +9%.  Vivos Therapeutics (VVOS) +7%. Genfit (GNFT) +6%. Losers: Outset Medical (OM) -31%. Arcellx (ACLX) -17%. Neptune Wellness Solutions NEPT -12%. H...

The American Society of Clinical Oncology (ASCO) held its annual meeting this week, and it's a must-show event for anybody pursuing cancer therapies. Our mini-roundtable has been digging into some of the presentations, and we found a few companies announcing nice surprises, among them, Ad...

Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...

ACLX is a clinical-stage biotech that aims to develop potentially "safer, more effective, and more broadly accessible" CAR-T cell therapies for cancers and incurable diseases. On June 3, ACLX presented p1 data of their lead candidate, CART-ddBCMA, for relapsed or refractory multiple m...

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting PR Newswire -- 100% ORR at both dose levels; deep and durable responses ob...

Biotechnology company Arcellx (NASDAQ:ACLX) appointed Michelle Gilson CFO. Gilson joins Arcellx from Canaccord Genuity. She most recently served as managing director and senior equity research analyst covering biotechnology companies at Canaccord Genuity. For further details see: ...

Arcellx Appoints Michelle Gilson as Chief Financial Officer PR Newswire FOSTER CITY, Calif. , May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies...

The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Investor Presentation - Slideshow